Scruggs, Brittni A.
Vasconcelos, Huber Martins Jr. http://orcid.org/0000-0001-5619-3188
Matioli da Palma, Mariana http://orcid.org/0000-0001-5770-279X
Kogachi, Katie
Pennesi, Mark E.
Yang, Paul
Bailey, Steven T.
Lauer, Andreas K. http://orcid.org/0000-0001-7582-9030
Funding for this research was provided by:
Heed Ophthalmic Foundation (Heed Fellowship Award)
Foundation Fighting Blindness (CD-NMT-0714-0648)
U.S. Department of Health & Human Services | National Institutes of Health (K08EY026650, P30EY010572)
U.S. Department of Health & Human Services | National Institutes of Health
Research to Prevent Blindness (Unrestricted grant to the Casey Eye Institute Department of Ophthalmology)
Article History
Received: 8 January 2021
Revised: 7 September 2021
Accepted: 15 September 2021
First Online: 28 September 2021
Competing interests
: AKL has received consulting fees or funds in support of clinical research from AGTC, Allergan, Atsena, Biogen, Cambridge Consulting, Genentech, IvericBio, Oxford BioMedic, Regenxbio, TeamedOn. MKP has received consulting fees from Adverum, AGTC, Allergan, Astellas Pharmaceuticals, Biogen, BlueRock, Editas, Iveric Bio, Novartis, Ora, RegenexBio, Roche, Viewpoint Therapeutics. MKP serves on the scientific advisor boards for Atsena, DTx Therapeutics, Endogena, Eyevensys, Horama, Nayan, Nacuity Pharmaceuticals, Ocugen, Sparing Vision, and Vedere. PY has received consulting fees from Adverum, AGTC, Nanoscope Therapeutics. All other authors declare no potential competing interests.
: Institutional Review Board approval at OHSU was obtained for review of all operative notes of patients receiving subretinal delivery of gene therapy.